Author of

• 11543

  +

  P2.06 - Poster Session 2 - Prognostic and Predictive Biomarkers (ID 165)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Biology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 11587

    +

    P2.06-044 - The influence of TP53 mutation on the prognosis of patients with early<br /> stage non-small cell lung cancer may depend on the intratumor<br /> heterogeneity of the mutation (ID 3083)

    09:30 - 09:30  |  Author(s): E.J. Lee
    • Abstract

    Background
    A large number of studies have evaluated the impact of TP53 mutation on the prognosis of patients with non-small cell lung cancer (NSCLC); however, the results of these studies are still controversial. Recently, considerable intratumor heterogeneity for genetic alterations has been demonstrated in various human cancers, including lung cancer.

    Methods
    In the present study, we evaluated TP53 mutations in NSCLCs by direct sequencing and observed remarkable variation in the values of the relative intensity (RI, the height of the peak of mutated allele/the height of the peak of non-mutated allele) of TP53 mutation. We also examined whether the RI values were associated with intratumor heterogeneity of TP53 mutation. In addition, we evaluated the relationship between TP53 mutation and survival outcome.

    Results
    The patients with TP53 mutation did not have significantly worse survival compared to those without the mutation. However, when tumors with TP53 mutation were categorized into two groups, those with a low and those with a high RI, the latter group had significantly worse survival compared to those with wild-type TP53 (adjusted hazard ratio = 2.58, 95% confidence interval = 1.21-5.48, P = 0.01), whereas the former group did not.

    Conclusion
    These results suggest that intratumor genetic heterogeneity may be an important factor in determining the role of TP53 mutation on the prognosis of NSCLC patients.